NCT06689085Phase 3Recruiting

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Study sponsor: Halozyme Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-03Estimated
Enrollment · participants100Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Oct 2027. After: Mar 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview